Awards

$106K

T1D Tolerance Induction with Natural Treg Epitopes

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 07/01/09 - 06/30/11
PI: Anne Searls Degroot

DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet cell antigen-specific T cells are either deleted in thymic development or are converted to T regulatory cells that actively suppress effector respons...

$285K

Optimization of a Multivalent Tuberculosis Vaccine

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 09/01/08 - 08/31/10
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit immunity to prevent reactivation of latent TB. This epitope-driven, DNA-prime, protein-boost TB vaccine has been in development since 1997, when ou...

$494K

T1D Tolerance Induction with Natural Treg Epitopes

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/08 - 06/30/09
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet cell antigen-specific T cells are either deleted in thymic development or are converted to T regulatory cells that actively suppress effector respons...

$264K

Epitope-driven deimmunization of Factor VIII

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/08 - 06/30/10
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophiliacs and greater than 50% of severe hemophiliacs produce antibodies (inhibitors) in response to treatment. Immunogenicity to Factor VIII (FVIII) is...

$300K

Optimization of a Multivalent Tuberculosis Vaccine

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 09/01/07 - 08/31/08
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit immunity to prevent reactivation of latent TB. This epitope-driven, DNA-prime, protein-boost TB vaccine has been in development since 1997, when ou...

$264K

Epitope-driven deimmunization of Factor VIII

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-34
Budget: 07/01/07 - 06/30/08
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophiliacs and greater than 50% of severe hemophiliacs produce antibodies (inhibitors) in response to treatment. Immunogenicity to Factor VIII (FVIII) is...

$528K

Novel Smallpox Vaccine Derived from VV/VAR Immunome

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 06/01/06 - 05/31/09
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to develop a safe, new smallpox vaccine based on epitopes conserved between the vaccinia virus (VV) and Variola (VAR) 'immunomes' that could be used as ...

$310K

A Genome-Derived, Epitope-Driven H. Pylori Vaccine

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 06/01/06 - 05/31/08
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based approach for the development of a therapeutic vaccine against Helicobacter pylori disease. First, the H. pylori genome will be scanned for immunodomina...

$410K

A Genome-derived, Epitope-driven Tularemia Vaccine

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAS-02-149
Budget: 09/01/05 - 08/31/07
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a rapid approach to the development of a tularemia vaccine that could be for BioDefense. First, F. tularensis genes that encode transmembrane, heat sh...

$300K

A Genome-Derived, Epitope-Driven H. Pylori Vaccine

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-04-27
Budget: 06/01/05 - 05/31/06
PI: Anne Searls De Groot

DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based approach for the development of a therapeutic vaccine against Helicobacter pylori disease. First, the H. pylori genome will be scanned for immunodomina...

Load More